glp 1 agonist approved for weight loss Comparing GLP-type therapies in those without diabetes. Two glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (#semaglutide and #liraglutide) and one dual (#tirzepatide) have been FDA-approved for #weightloss in adults Frontiers | GLP−1 receptor agonists

GLP-1 drugs have become a game-changer in treating obesity and type 2 diabetes, forecast to reach a $100 billion market value by 2030

Moreover, it remains to be shown that GIPR agonism can improve insulin secretion in type 2 diabetic patients who have been noted in previous studies to be unresponsive to GIP

If you're on medications or managing a health condition, check with your provider before use

GLP-1s like Ozempic, Wegovy, and Mounjaro have gained a lot of media attention for weight loss, but how do these weight-loss injections work

These cost-saving results have implications for patients, physicians, insurers, and governments

Real-world data show early discontinuation of GLP-1 therapy is linked to higher risks of coronary artery disease and heart failure.